Gaurav Joshi

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 16

Top Venues

Journal of medicinal chemistry

RSC medicinal chemistry

Human vaccines & immunotherapeutics

The Journal of organic chemistry

Central University of Punjab

Central University of Punjab (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Central University of Punjab Nov 17o 2014 - Aug 9o 2015

India

Project Fellow :: Centre for Pharmaceutical Sciences and Natural Products

Education History

Central University of Punjab Aug 10o 2015

India

PHD :: Pharmaceutical Sciences and Natural Products

Publications

Pritam Maity, Joydeep Chatterjee, Kiran T Patil, Sahil Arora, Madhurendra K Katiyar, Manvendra Kumar, Amirreza Samarbakhsh, Gaurav Joshi, Priyadeep Bhutani, Manoj Chugh, Navnath S Gavande, Raj Kumar
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. Journal of medicinal chemistry (2023)
Sandhya Chahal, Jyoti Punia, Payal Rani, Rajvir Singh, null Mayank, Parvin Kumar, Ramesh Kataria, Gaurav Joshi, Jayant Sindhu
Development of thiazole-appended novel hydrazones as a new class of α-amylase inhibitors with anticancer assets: an in silico and in vitro approach. RSC medicinal chemistry 14 (4) (2023)
Pritam Maity, Joydeep Chatterjee, Kiran T Patil, Sahil Arora, Madhurendra K Katiyar, Manvendra Kumar, Amirreza Samarbakhsh, Gaurav Joshi, Priyadeep Bhutani, Manoj Chugh, Navnath S Gavande, Raj Kumar
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. Journal of medicinal chemistry 66 (5) (2023)
Pritam Maity, Joydeep Chatterjee, Kiran T Patil, Sahil Arora, Madhurendra K Katiyar, Manvendra Kumar, Amirreza Samarbakhsh, Gaurav Joshi, Priyadeep Bhutani, Manoj Chugh, Navnath S Gavande, Raj Kumar
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. Journal of medicinal chemistry 66 (5) (2023)
Sandhya Chahal, Payal Rani, null Kiran, Jayant Sindhu, Gaurav Joshi, Aravindhan Ganesan, Subha Kalyaanamoorthy, null Mayank, Parvin Kumar, Rajvir Singh, Arvind Negi
Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective. ACS omega 8 (20) (2023)
Kapil Kumar Goel, Somesh Thapliyal, Rajeev Kharb, Gaurav Joshi, Arvind Negi, Bhupinder Kumar
Imidazoles as Serotonin Receptor Modulators for Treatment of Depression: Structural Insights and Structure-Activity Relationship Studies. Pharmaceutics 15 (9) (2023)
Pritam Maity, Joydeep Chatterjee, Kiran T Patil, Sahil Arora, Madhurendra K Katiyar, Manvendra Kumar, Amirreza Samarbakhsh, Gaurav Joshi, Priyadeep Bhutani, Manoj Chugh, Navnath S Gavande, Raj Kumar
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. Journal of medicinal chemistry 66 (5) (2023)
Sandhya Chahal, Jyoti Punia, Payal Rani, Rajvir Singh, null Mayank, Parvin Kumar, Ramesh Kataria, Gaurav Joshi, Jayant Sindhu
Development of thiazole-appended novel hydrazones as a new class of α-amylase inhibitors with anticancer assets: an in silico and in vitro approach. RSC medicinal chemistry 14 (4) (2023)
Gaurav Joshi, Ramarao Poduri
Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy. Human vaccines & immunotherapeutics 18 (1) (2022)
Zahid Rafiq Bhat, Manvendra Kumar, Nisha Sharma, Umesh Prasad Yadav, Tashvinder Singh, Gaurav Joshi, Brahmam Pujala, Mohd Raja, Joydeep Chatterjee, Kulbhushan Tikoo, Sandeep Singh, Raj Kumar
In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2- a ]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice. Molecules (Basel, Switzerland) 27 (17) (2022)
Elagandhula Sathish, Arshad J Ansari, Gaurav Joshi, Akansha Pandit, Monika Shukla, Neha Kumari, Ashoke Sharon, Ved Prakash Verma, Devesh M Sawant
Pd-Catalysed [3 + 2]-cycloaddition towards the generation of bioactive bis-heterocycles/identification of COX-2 inhibitors via in silico analysis. Organic & biomolecular chemistry 20 (23) (2022)
Sahil Arora, Gaurav Joshi, Anuhar Chaturvedi, Michael Heuser, Santoshkumar Patil, Raj Kumar
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2. Journal of medicinal chemistry (2021)
Gaurav Joshi, Pobitra Borah, Shweta Thakur, Praveen Sharma, null Mayank, Ramarao Poduri
Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go? Human vaccines & immunotherapeutics (2021)
Priyadeep Bhutani, Gaurav Joshi, Nivethitha Raja, Namrata Bachhav, Prabhakar K Rajanna, Hemant Bhutani, Atish T Paul, Raj Kumar
U.S. FDA Approved Drugs from 2015-June 2020: A Perspective. Journal of medicinal chemistry 64 (5) (2021)
Iliyas Khan, Gaurav Joshi, Bibekananda Sarkar, Kartik T Nakhate, null Ajazuddin, Anil K Mantha, Raj Kumar, Ankur Kaul, Shubhra Chaturvedi, Anil K Mishra, Umesh Gupta
Doxorubicin and Crocin Co-delivery by Polymeric Nanoparticles for Enhanced Anticancer Potential In Vitro and In Vivo . ACS applied bio materials 3 (11) (2020)
Arshad J Ansari, Gaurav Joshi, Praveen Sharma, Antim K Maurya, Ramesh K Metre, Vijai K Agnihotri, Chanchayya Gupta Chandaluri, Raj Kumar, Sandeep Singh, Devesh M Sawant
Pd-Catalyzed Four-Component Sequential Reaction Delivers a Modular Fluorophore Platform for Cell Imaging. The Journal of organic chemistry 84 (7) (2019)

Gaurav Joshi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Gaurav Joshi